

**Amendments to the Claims:**

1-4. cancelled. Please cancel claims 1-4 without prejudice.

5. (currently amended) The compound of claim 27 [[4]] wherein:

substituent(s) on E is(are) independently substituted or unsubstituted alkyl, halogen, hydroxy, ester, -S-alkyl, NO<sub>2</sub> or SO<sub>2</sub>;

substituent(s) on G is(are) independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, halogen, amide, amine, hydroxy, sulfonyl, sulfonamide, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-amine, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-heterocycle, or -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-amide, wherein n and m are independently 0, 1, 2, 3, 4 or 5; and

substituent(s) on J is(are) independently substituted or unsubstituted alkyl, halogen, ether, -S-alkyl, or -S-aryl.

6. (original) The compound of claim 5, wherein:

substituent(s) on E and J is(are) halogen; and

substituent(s) on G is(are) halogen and/or substituted alkyl.

7-19 (withdrawn)

20. (currently amended) A composition comprising a compound according to claim 27 + in a pharmaceutically acceptable carrier therefor.

21. (currently amended) A method of modulating the level of Amyloid Beta Precursor Protein (APP), said method comprising contacting said protein with at least one compound according to claim 27 +.

22. (original) A method according to claim 21, wherein said APP is APP<sub>751</sub>, APP<sub>695wt</sub>, APP<sub>670/671</sub>, APP<sub>670/671/717</sub>, sAPP, α-sAPP, or β-sAPP.